HOUSE_OVERSIGHT_024101.jpg

1.22 MB
View Original

Extraction Summary

0
People
24
Organizations
0
Locations
0
Events
1
Relationships
3
Quotes

Document Information

Type: Financial investment schedule / appendix
File Size: 1.22 MB
Summary

This document is a confidential financial appendix detailing the investment portfolio of New Leaf Ventures I, L.P. as of March 31, 2014. It lists specific realized and unrealized investments in healthcare and therapeutics companies, providing data on vintage years, costs, values, and gross internal rates of return (IRR). The document is marked with a House Oversight control number, suggesting it is part of a larger investigation, likely involving financial scrutiny.

Organizations (24)

Name Type Context
New Leaf Ventures I, L.P.
Aesthetic Sciences Corporation
Artisan Pharma, Inc.
Aviir, Inc.
Barrier Therapeutics, Inc.
BioRelix, Inc.
Cerexa, Inc.
CN Therapeutics, Inc.
Interlace Medical, Inc.
Oriel Therapeutics, Inc.
Pearl Therapeutics, Inc.
Proteogenix, Inc.
Stromedix, Inc.
Transcept Pharmaceuticals, Inc
Access Closure, Inc.
Concert Pharmaceuticals, Inc.
Direct Flow Medical, Inc.
IlluminOss Medical, Inc.
Intarcia Therapeutics, Inc.
Relypsa, Inc.
ReShape Medical
Tioga Pharmaceuticals, Inc.
VaxInnate, Inc.
House Oversight Committee

Relationships (1)

New Leaf Ventures I, L.P. Investment Various Portfolio Companies
Table lists New Leaf Ventures I, L.P. investments in companies such as Intarcia Therapeutics, Pearl Therapeutics, etc.

Key Quotes (3)

"$ amounts in millions, as of March 31, 2014"
Source
HOUSE_OVERSIGHT_024101.jpg
Quote #1
"CONTROL NUMBER 257 - CONFIDENTIAL"
Source
HOUSE_OVERSIGHT_024101.jpg
Quote #2
"HOUSE_OVERSIGHT_024101"
Source
HOUSE_OVERSIGHT_024101.jpg
Quote #3

Discussion 0

Sign in to join the discussion

No comments yet

Be the first to share your thoughts on this epstein document